MCC950 sodium
MCC950 sodium (CAS 256373-96-3) is a selective small-molecule inhibitor targeting the NOD-like receptor family protein 3 (NLRP3) inflammasome. MCC950 sodium inhibits NLRP3 activation in murine bone marrow-derived macrophages (BMDMs) with an IC50 of 7.5 nM and demonstrates comparable selectivity and potency in human monocyte-derived macrophages (HMDMs). It specifically blocks both canonical and noncanonical activation pathways without affecting other inflammasomes such as AIM2, NLRC4, and NLRP1. Due to its selectivity, MCC950 sodium is valuable in investigating NLRP3-associated inflammatory and autoimmune conditions.
- 1. Linkang Zhou, Xiaoxue Qiu, et al. "Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation." Sci Transl Med. 2024 Mar 13;16(738):eadk1866. PMID: 38478630
- 2. Longfei Du, Xuyuan Fan, et al. "Quercetin Ameliorates Cognitive Impairment in Depression by Targeting HSP90 to Inhibit NLRP3 Inflammasome Activation." Mol Neurobiol. 2024 Feb 8. PMID: 38329680
- 3. Chaohong Li, Zhen Zhao, et al. "NLRP3-GSDMD-dependent IL-1β Secretion from Microglia Mediates Learning and Memory Impairment in a Chronic Intermittent Hypoxia-induced Mouse Model." Neuroscience. 2024 Feb 16:539:51-65. PMID: 38154620
- 4. Abbie Tomes, BSc (Hons), et al. "Activation of the inflammasome in bovine mammary macrophages by Streptococcus uberis." University of Nottingham, September 2023.
- 5. Yejing Zhu, Jinyu Chi, et al. "High-dose remifentanil exacerbates myocardial ischemia-reperfusion injury through activation of calcium-sensing receptor-mediated pyroptosis." Int J Med Sci. 2023 Sep 18;20(12):1570-1583. PMID: 37859698
- 6. Jiaxin He, Jialin Cui, et al. "Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis." J Diabetes Res. 2023 May 22:2023:7423661. PMID: 37261217
| Storage | Store at -20°C |
| M.Wt | 426.46 |
| Cas No. | 256373-96-3 |
| Formula | C20H23N2NaO5S |
| Synonyms | CRID3 sodium salt |
| Solubility | ≥124 mg/mL in H2O; ≥21.45 mg/mL in DMSO; ≥43 mg/mL in EtOH |
| Chemical Name | sodium ((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((4-(2-hydroxypropan-2-yl)furan-2-yl)sulfonyl)amide |
| SDF | Download SDF |
| Canonical SMILES | O=S([N-]C(NC1=C2CCCC2=CC3=C1CCC3)=O)(C4=CC(C(O)(C)C)=CO4)=O.[Na+] |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Bone marrow derived macrophages (BMDMs), human monocyte–derived macrophages (HMDMs), and human peripheral blood mononuclear cells (PBMCs) |
|
Reaction Conditions |
0.001 ~ 10 μM MCC950 sodium for 30 min incubation |
|
Applications |
Treating cells with nanomolar concentrations of MCC950 sodium dose-dependently inhibited the release of interleukin-1β (IL-1β) in BMDMs, HMDMs, and PBMCs. LPS-dependent tumor necrosis factor-α (TNF-α) secretion was not impaired by MCC950 sodium, which demonstrated that the inhibition effect of MCC950 sodium on IL-1β secretion was specific. |
| Animal experiment:[1] | |
|
Animal models |
C57BL/6 mice |
|
Dosage form |
10 and 50 mg/kg Injected intraperitoneally (i.p.) |
|
Applications |
In mice intraperitoneally injected with lipopolysaccharides (LPS), pre-treatment with MCC950 sodium (50 mg/kg, i.p., 1 h before LPS injection) reduced serum concentrations of IL-1β and IL-6 while it did not considerably decrease the amount of TNF-α. Furthermore, MCC950 sodium (10 mg/kg, i.p.) attenuated the severity of experimental autoimmune encephalomyelitis, a disease model of multiple sclerosis. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Coll RC, Robertson AA, Chae JJ. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 2015, 21(3): 248-255. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
